Y-Intercept (HK)’s Allogene Therapeutics ALLO Stock Holding History

Y-Intercept (HK)’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-43,940	Closed	-$64.2K	–	1609
2025 Q1	$64.2K	Buy	+43,940	New	+$82.8K	﹤0.01%	1125
2024 Q1	–	Sell	-54,369	Closed	-$175K	–	1328
2023 Q4	$175K	Buy	+54,369	New	+$154K	0.02%	1025
2022 Q3	–	Sell	-18,422	Closed	-$210K	–	939
2022 Q2	$210K	Buy	+18,422	New	+$164K	0.03%	667

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Y-Intercept (HK)'s ALLO Position: Q2 2025 in Review

Y-Intercept (HK) sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 43,940 shares — an estimated $64.2K sold.

Y-Intercept (HK) first reported a position in ALLO in Q2 2022 and held it in 3 quarters. The position peaked at $210K in Q2 2022. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

Y-Intercept (HK) reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
Y-Intercept (HK) sold 43,940 Allogene Therapeutics shares in Q2 2025, an estimated $64.2K.
Y-Intercept (HK) first reported a position in Allogene Therapeutics in Q2 2022 and held it in 3 quarters.
Y-Intercept (HK)'s Allogene Therapeutics position peaked at $210K in Q2 2022.
158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.